Free Trial

Vanguard Personalized Indexing Management LLC Has $4.39 Million Position in Biogen Inc. $BIIB

Biogen logo with Medical background

Key Points

  • Vanguard Personalized Indexing Management LLC increased its stake in Biogen Inc. by 60.9%, bringing their total holdings to 34,928 shares worth approximately $4.39 million as of the end of the latest quarter.
  • Research firms have rated Biogen with a consensus of "Hold" and an average target price of $180.69, with eleven analysts issuing a "Buy" rating.
  • Biogen reported a $5.47 earnings per share in its last quarterly results, exceeding expectations and reflecting a year-over-year revenue growth of 7.3%.
  • Five stocks we like better than Biogen.

Vanguard Personalized Indexing Management LLC boosted its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 60.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 34,928 shares of the biotechnology company's stock after purchasing an additional 13,226 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in Biogen were worth $4,387,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Generali Investments CEE investicni spolecnost a.s. grew its position in Biogen by 43.2% in the 2nd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 38,755 shares of the biotechnology company's stock valued at $4,867,000 after purchasing an additional 11,695 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its position in Biogen by 6.5% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 416,960 shares of the biotechnology company's stock valued at $57,057,000 after purchasing an additional 25,464 shares during the period. Asset Management One Co. Ltd. grew its position in Biogen by 5.5% in the 1st quarter. Asset Management One Co. Ltd. now owns 61,420 shares of the biotechnology company's stock valued at $8,405,000 after purchasing an additional 3,194 shares during the period. Point72 Europe London LLP acquired a new stake in Biogen in the 1st quarter valued at $11,286,000. Finally, Motley Fool Asset Management LLC boosted its holdings in Biogen by 64.7% during the 1st quarter. Motley Fool Asset Management LLC now owns 6,809 shares of the biotechnology company's stock worth $932,000 after acquiring an additional 2,676 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

Analyst Ratings Changes

A number of research firms have issued reports on BIIB. Wall Street Zen raised shares of Biogen from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 28th. Truist Financial began coverage on shares of Biogen in a report on Monday, July 21st. They set a "hold" rating and a $142.00 price objective on the stock. Morgan Stanley lifted their price objective on shares of Biogen from $144.00 to $149.00 and gave the stock an "equal weight" rating in a report on Friday. Rothschild & Co Redburn lifted their price objective on shares of Biogen from $149.00 to $150.00 and gave the stock a "neutral" rating in a report on Monday, October 6th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Biogen in a report on Wednesday, September 24th. Eleven research analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $180.69.

Check Out Our Latest Research Report on BIIB

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 517 shares of the company's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $133.55, for a total transaction of $69,045.35. Following the sale, the insider directly owned 5,772 shares of the company's stock, valued at $770,850.60. This represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.18% of the stock is currently owned by company insiders.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $145.31 on Wednesday. The company's 50-day moving average is $140.71 and its 200 day moving average is $131.23. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.79 and a current ratio of 2.50. The company has a market capitalization of $21.31 billion, a P/E ratio of 13.89, a price-to-earnings-growth ratio of 1.14 and a beta of 0.13. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $194.13.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share for the quarter, topping analysts' consensus estimates of $3.93 by $1.54. The company had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.32 billion. Biogen had a net margin of 15.31% and a return on equity of 13.85%. The firm's quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the firm earned $5.28 EPS. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS. On average, equities research analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current year.

About Biogen

(Free Report)

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

Read More

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Biogen Right Now?

Before you consider Biogen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.

While Biogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.